Atrial Fibrillation Clinical Trial
— TrAFFICOfficial title:
Tracking Atrial Fibrillation After Intensive Care Admission
Atrial fibrillation (AF) is a heart problem that causes an irregular heartbeat. It can cause the heart to beat more rapidly and reduce the heart's ability to pump blood around the body efficiently, causing heart failure. It also increases the risk of blood clots forming inside the heart. These clots may then be pumped out of the heart, through the blood vessels, to other parts of the body. This can cause strokes if the clots spread to the brain. AF is a common problem outside an Intensive Care Unit (ICU), where treatment is based on good, evidence-based guidelines designed to reduce the risk of problems like heart failure or strokes. Around 10% of patients treated in ICU develop atrial fibrillation as a complication of their underlying illness. Some patients will recover their normal heart rhythm before leaving the ICU, often with the help of some medical treatments. It is not known whether these patients will get AF again after leaving the ICU, or when this is likely to happen. It is also unknown whether patients who avoid AF whilst on the ICU may still be at high risk of developing it after they leave. This study will identify patients on the ICU who have no previous record of atrial fibrillation. These patients will be monitored whilst on the ICU to identify those who develop AF. Those patients who develop new onset AF will be monitored on the ward after leaving the ICU to see which patients have AF at this point. The heart monitoring will be repeated once the patients leave hospital, again to identify whether they have atrial fibrillation. Some studies suggest that AF during critical illness causes a long-term risk of recurrent AF and AF associated complications such as heart failure, stroke, and death. To understand how to minimise these risks in intensive care patients, we need to know how which patients who develop atrial fibrillation whilst in an ICU go on to have recurrent atrial fibrillation in hospital and in the community. These patients may benefit from interventions to reduce long term adverse events such as anticoagulation to reduce stroke risk.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 30, 2025 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Willing and able to give informed consent for participation in the study, or favourable consultee advice for adults lacking capacity - Male or Female, - aged 16 years or above. - Admitted to intensive care for >24 hours - New onset atrial fibrillation as confirmed by 12 lead ECG- Exclusion Criteria: - History of atrial fibrillation - Unable to undergo cardiac monitoring - Previously included in the study - Not anticipated by treating consultant to survive to ICU discharge (withdrawal or limitation of medical treatment at time of screening) - Contraindication to anticoagulation - Unable to wear the device for the prescribed monitoring period - Implanted neurostimulator, as this may disrupt the ECG recording |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Oxford University Hospitals Trust | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Proportion of AF episodes detected compared to a. Validated CE marked algorithm b. Compared to 3 best-in-class algorithms | 3 months post hospital discharge | ||
Other | Identify subgroups of patients that are at increased risk of adverse outcomes of new onset atrial fibrillation in ICU compared to those who are not. | Perform subgroup analysis of results in both study groups, adverse outcomes defined as stroke, TIA, bleeding complications | At completion of study at 3 months post hospital discharge. | |
Primary | Proportion of eligible patients who are willing to participate in the study | 3 months post hospital discharge | ||
Primary | Proportion of patients who are compliant with the study protocol | 3 months post hospital discharge | ||
Primary | Proportion of patients lost to follow up | 3 months post hospital discharge | ||
Secondary | Proportion of patients who are in AF post ICU discharge in hospital. | 14 days post ICU hospital discharge | ||
Secondary | Proportion of patients who are in AF at 3 months post hospital discharge | 3 months post hospital discharge | ||
Secondary | Proportion of patients who develop NOAF in ICU who develop stroke or TIA post ICU discharge | 14 days post ICU discharge | ||
Secondary | Proportion of patients who develop NOAF in ICU who develop stroke or TIA post hospital discharge | 3 months post hospital discharge | ||
Secondary | Difference in hospital length of stay in patients who develop atrial fibrillation after ICU discharge compared to patients who do not. | To compare patients who develop NOAF in ICU and have recurrent AF in hospital with those who do not have recurrent AF in hospital | Follow up patient appointment at 3 months post hospital discharge. | |
Secondary | Difference in number of ICU readmissions in patients who develop atrial fibrillation after ICU discharge compared to those who do not. | To compare patients who develop NOAF in ICU and have recurrent AF in hospital with those who do not have recurrent AF in hospital | Follow up patient appointment at 3 months post hospital discharge. | |
Secondary | Difference in mortality in patients who develop atrial fibrillation after ICU discharge compared to those who do not. | To compare patients who develop NOAF in ICU and have recurrent AF in hospital and/or post hospital discharge with those who do not have recurrent AF. | From ICU discharge to follow up patient appointment at 3 months post hospital discharge. | |
Secondary | Proportion of patients who develop NOAF in ICU who develop bleeding complications post ICU discharge. | Major and minor bleeding episodes as defined by the International Society on Thrombosis and Haemostasis Criteria. | From ICU discharge to 14 days post ICU discharge | |
Secondary | Proportion of patients who develop NOAF in ICU who develop bleeding complications post hospital discharge. | Major and minor bleeding episodes as defined by the International Society on Thrombosis and Haemostasis Criteria. | 3 months post hospital discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |